2 Under-the-Radar Stocks That Have Soared This Year

Group 1: TransMedics Group - TransMedics Group is innovating the organ transplant market by addressing the challenges of organ storage and preservation, which traditionally has poor outcomes with cold storage methods [2][3] - The company developed the Organ Care System (OCS), which maintains organs in optimal condition for transplant, achieving a usage rate of 87% for lungs compared to 23% for cold storage, leading to fewer post-transplant complications [3] - In Q3, TransMedics reported revenue of $143.8 million, a 32% increase year-over-year, with net earnings per share rising to $0.66 from $0.12 [6] - The company is expanding its National OCS Program (NOP) to improve organ procurement and transport, which has been crucial for business growth [8] - TransMedics has partnered with Mercedes-Benz for ground transport in Italy, aiming to enhance its service in Europe, which could positively impact revenue [9] - The company is also developing a next-generation OCS system for other organs, anticipating steady growth in organ transplants over the coming years [10] Group 2: Abivax Société Anonyme - Abivax is a clinical-stage biotech company based in France, focusing on the development of obefazimod for ulcerative colitis (UC), which has shown promising late-stage clinical trial results [11] - The competitive landscape for UC treatments includes established therapies from major pharmaceutical companies, but Abivax's obefazimod could target a larger patient pool, particularly those with inadequate responses to existing therapies [12][13] - The stock has surged over 1,000% since January, with a market cap of approximately $9 billion, indicating strong investor interest [14][15] - Abivax plans to submit for regulatory approval in the U.S. in the second half of 2026, contingent on the success of ongoing trials, and is also exploring other indications for obefazimod, such as Crohn's disease [15] - Despite the potential for obefazimod to achieve blockbuster status, there are risks associated with regulatory and clinical trial outcomes, making it a high-risk investment [16][17]